Search results for "Fungal Infection"

showing 6 items of 46 documents

Fungal infections in transplantation patients

2003

Invasive fungal infections have became one of the principal obstacles to successful solid organ and bone marrow transplantation. The natural history and incidence of systemic fungal infection varies with the type of organ transplanted and the immunosuppressive therapy administered; the majority of infections occur within the first two months after transplantation. The most common fungi that cause disease in transplant recipients are Candida spp. and Aspergillus spp. The clinical presentations of fungal infections in solid-organ transplant recipients are non specific and often overlap with other infectious and non infectious processes; for this reason it's important maintain a high index of …

Settore MED/17 - Malattie Infettivetransplantation patients Invasive fungal infections
researchProduct

MONITORING AND USE OF ANTIMYCOTICS FOR SYSTEMIC USE SUPPLIED BY THE STATE HOSPITAL PHARMACY OF MARSALA (TP), ITALY: MYCAMINE® (MICAFUNGIN)

2014

Micafungin is an antimycotic drug and represents an important addition to the available therapies for the treatment of systemic fungal infections. Micafungin is used in the treatment of invasive candidiasis, oesophageal and prophylaxis of Candida infections. It inhibits, in a non-competitive way, the synthesis of 1,3-b-D-glucan, a component of fungal cell wall and is rapidly distributed into the tissues. It has a high-rate bond with respect to plasma protein; the above mentioned bond is independent from the concentration of the drug. It is metabolized through the liver, being not subject to intense metabolic transformations until the excretion. There is no evidence of systemic accumulation …

fungal infections Micafungin antimycotic drug
researchProduct

Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial.

2011

Background: Lactoferrin is a mammalian milk glycoprotein involved in innate immunity. Recent data show that bovine lactoferrin (bLF) prevents late-onset sepsis in preterm very low birth weight (VLBW) neonates. Methods: This is a secondary analysis of data from a multicenter randomized controlled trial where preterm VLBW neonates randomly received bLF (100 mg/day; group A1), bLF + Lactobacillus rhamnosus GG (106 colony-forming units per day; group A2), or placebo (group B) for 6 weeks. Here we analyze the incidence rates of fungal colonization, invasive fungal infection (IFI), and rate of progression from colonization to infection in all groups. Results: This study included 472 neonates who…

fungal sepsisDiseasesInfant Premature DiseasesPediatricsGastroenterologylactoferrin; VLBW neonates; Candida; fungal sepsis; prophylaxisGroup BSettore MED/38 - Pediatria Generale E SpecialisticaAnti-Infective AgentsInfant Very Low Birth WeightCandidabiologyLactoferrinBovine lactoferrin fungal infections very low birth weight newbornsPerinatology and Child Healthlactoferrinprophylaxismedicine.symptomInfant Prematuremedicine.medical_specialtyFungal sepsisPlaceboSepsisLactobacillus rhamnosusIntolerancesInternal medicinemedicineAnimalsHumansfungal sepsiAdverse effectPrematureProphylaxisbusiness.industryVery Low Birth WeightProbioticsInfant NewbornInfantNewbornbiology.organism_classificationmedicine.diseaseLactoferrinLow birth weightMycosesVLBW neonatesPediatrics Perinatology and Child HealthImmunologyCandida; Fungal sepsis; Lactoferrin; Prophylaxis; VLBW neonates; Animals; Anti-Infective Agents; Cattle; Humans; Infant Newborn; Infant Premature; Infant Premature Diseases; Lactoferrin; Mycoses; Probiotics; Infant Very Low Birth Weight; Pediatrics Perinatology and Child Healthbiology.proteinCattlebusiness
researchProduct

The Effects of Oregano Oil on Fungal Infections Associated with Metabolic Syndrome

2020

International audience; This study aims to compare the evolution of mycosis associated with metabolic syndrome under allopathic treatment compared to phytotherapy using oregano essential oil. The study was conducted over a period of 6 months, on a total of 72 patients diagnosed with fungal infections associated with metabolic syndrome. The patients were divided into 3 groups, depending on the administered treatment: group 1: 24 patients who received allopathic treatment; group 2: 24 patients who received oregano oil treatment; group 3: control, which did not undergo any antifungal treatment. All three groups were subjected to specific diet therapy for mycosis. The patients were initially ev…

medicine.medical_specialtyDiet therapyItraconazoleMaterials Science (miscellaneous)010402 general chemistry01 natural sciencesGastroenterologyGeneral Biochemistry Genetics and Molecular Biologylaw.inventionFungal infectionsOregano oillawInternal medicineMaterials ChemistrymedicineGeneral Pharmacology Toxicology and PharmaceuticsMycosisProcess Chemistry and TechnologyGeneral EngineeringGeneral ChemistryGeneral Medicinemedicine.disease3. Good health0104 chemical sciencesNystatinTolerabilityMetabolic X syndrome[SDE]Environmental SciencesMetabolic syndromePhytotherapyFluconazolemedicine.drug
researchProduct

The paradox of the evidence about invasive fungal infections prevention

2016

Invasive fungal infections (IFIs) are characterized by high morbidity and mortality in non-neutropenic critically ill patients. Attributable mortality due to Candida spp. infections ranges from about 42 to 63 % [1, 2]. Data from large observational and retrospective studies show an association between early antifungal treatment and improved survival [3, 4]. Updated clinical practice guidelines for the management of candidiasis have been recently published [5]. In 2006, Playford et al. published a Cochrane systematic review investigating the use of antifungal agents for prevention of IFIs in non-neutropenic critically ill patients [6]. In that review, the outcome of proven IFI was defined as…

medicine.medical_specialtyPediatricsAntifungal AgentsUrinary systemMEDLINECritical Care and Intensive Care Medicinelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAntifungal AgentHumansInfection controlInvasive Fungal Infection030212 general & internal medicinebusiness.industryAntifungal Agents; Humans; Invasive Fungal Infections; Critical Care and Intensive Care Medicine030208 emergency & critical care medicineRetrospective cohort studyFungal EsophagitisEditorialmedicine.anatomical_structureObservational studybusinessInvasive Fungal InfectionsHumanRespiratory tractCritical Care
researchProduct

Mucocutaneous diseases with manifestations in the head and neck region: 24 years of experience in a Dermatology service

2023

This study aimed to evaluate the clinicopathological features of mucocutaneous diseases with manifestation in the head and neck region. A retrospective analysis of a dermatology reference center database was carried out. Over 24 years. Clinicopathological data were collected from medical records and the data was analyzed by descriptive statistics. A total of 11.538 medical records were analyzed, being 152 cases of mucocutaneous diseases with manifestations in the head and neck region. Cutaneous lupus erythematosus was the most prevalent diagnosis (66.4%). Face (44.1%), females (79.6%), and patients with 45 years mean age were the most common features. In the oral cavity, the most affected r…

oral mucosaparacoccidioidomycosisOtorhinolaryngologyfungal infectionneglected diseasesoral medicineSurgerymycosesGeneral Dentistryoral manifestationsUNESCO:CIENCIAS MÉDICASsouth american blastomycosisMedicina Oral Patología Oral y Cirugia Bucal
researchProduct